Multiple myeloma (MM) is not a disease with a known cure, but recent studies have suggested that focusing on boosting immunity in patients with MM may help their chances at longer-term survival. What are these immunity-focused treatment options?
In the B-43 phase 3 trial, researchers did not achieve the objective of a 36% reduction in ipsilateral breast cancer rate with the addition of trastuzumab to radiotherapy.
Oxaliplatin-based hyperthermic intraperitoneal chemotherapy showed no OS benefit compared with cytoreductive surgery in patients with colorectal peritoneal metastases.
